SIGA SIGA Dashboard

SIGA Technologies, Inc. engages in the development and commercialization of solutions for serious unmet medical needs and biothreats. The company develops therapeutic solutions for lethal pathogens including smallpox, Ebola, dengue, Lassa fever, and other dangerous viruses. It offers an orally administered antiviral drug that targets orthopoxviruses under the TPOXX brand. The company was founded by Steven Oliveira on December 28, 1995 and is headquartered in New York, NY.

Company profile

Ticker

SIGA

Exchange

NASDAQ

Website

www.siga.com

CEO

Phillip Louis Gomez

Incorporated

Delaware

Location

New York

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Merck & Co • Allergan • Johnson & Johnson • Abbott Laboratories • Teva- Pharmaceutical Industries • Viatris • Bristol-Myers Squibb • Lilly(Eli) & Co • Warner Chilcott ...

Former names

SIGA PHARMACEUTICALS INC

SEC CIK

0001010086

Corporate docs

Articles of Incorporation & Bylaws

IRS number

133864870

SIGA stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

A Look Into Healthcare Sector Value Stocks

29 Mar 21

What is a Value Stock?

SIGA Technologies Reports Strategic Partnership With Cipla Therapeutics' USA Unit To Deliver Sustained Innovation, Access To Novel Antibacterial Drugs

23 Mar 21

Cipla Therapeutics, a division of Cipla USA Inc., an affiliate of Cipla Limited (BSE: 500087; NSE: CIPLA EQ; referred to as "Cipla") and SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a commercial-stage

5 Value Stocks In The Healthcare Sector

15 Mar 21

The Meaning Behind Value Stocks

SIGA Technologies Q4 EPS $0.26 Up From $(0.06) YoY, Sales $37.80M Up From $4.26M YoY

4 Mar 21

Earnings Scheduled For March 4, 2021

4 Mar 21

Press releases

Pro users get this 30m faster

Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats

23 Mar 21

MUMBAI, India, March 23, 2021 /PRNewswire/ -- Cipla Therapeutics, an affiliate of Cipla Limited (BSE: 500087) (NSE: CIPLA EQ) (herein referred to as "Cipla") and SIGA Technologies, Inc. (SIGA) (NASDAQ:SIGA), a

SIGA Reports Financial Results for Three and Twelve Months Ended December 31, 2020

4 Mar 21

- Approximately 363,000 Courses of Oral TPOXX® Delivered to U.S. Government in 2020 – - International Contracts for the Purchase of up to Approximately $47 Million of Oral TPOXX® Since April 2020 – -

SIGA Technologies, Inc. to Host Earnings Call

4 Mar 21

NEW YORK, NY / ACCESSWIRE / March 4, 2021 / SIGA Technologies, Inc. (NASDAQ:SIGA) will be discussing their earnings results in their 2020 Fourth Quarter Earnings call to be held on March 4, 2021 at 4:30 PM Eastern

SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results

26 Feb 21

SIGA Announces Public Health Agency of Canada Contract Award to Purchase Up To Approximately $33 Million of Oral TPOXX®

13 Jan 21

Calendar

4 Mar 21

11 Apr 21

31 Dec 21

Financial summary

Financial statements Chart SIGA financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 20	Dec 19	Dec 18	Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from SIGA earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	117.89M	117.89M	117.89M	117.89M	117.89M	117.89M
Cash burn (monthly)	(positive/no burn)	3.59M	(positive/no burn)	(positive/no burn)	(positive/no burn)	(positive/no burn)
Cash used (since last report)	n/a	12.12M	n/a	n/a	n/a	n/a
Cash remaining	n/a	105.78M	n/a	n/a	n/a	n/a
Runway (months of cash)	n/a	29.5	n/a	n/a	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

SIGA insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
10 Dec 20	Julian Nemirovsky	Stock Option Common Stock, par value $.0001 per share	Grant	Aquire A	No	No	7	25,000	175K	25,000
27 Aug 20	Antal James	Common Stock, Par Value $.0001 Per Share	Sell	Dispose S	No	No	7.1	30,000	213K	115,875
6 Aug 20	Edward P. Taibi	Stock Option Common Stock, par value $.0001 per share	Grant	Aquire A	No	No	6.52	25,000	163K	25,000
6 Aug 20	Edward P. Taibi	RSU Common Stock, par value $.0001 per share	Grant	Aquire A	No	No	0	15,000	0	15,000

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

SIGA institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

32.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	98	103	-4.9%
Opened positions	9	20	-55.0%
Closed positions	14	10	+40.0%
Increased positions	32	30	+6.7%
Reduced positions	35	33	+6.1%

13F shares	Current	Prev Q	Change
Total value	266.62M	639.38M	-58.3%
Total shares	24.84M	22.66M	+9.6%
Total puts	0	16.9K	EXIT
Total calls	68K	17.1K	+297.7%
Total put/call ratio	–	1.0	–

Largest owners	Shares	Value	Change
BLK Blackrock	4.54M	$33.04M	-1.6%
Esopus Creek Value Series Fund LP - Series A	3.49M	$25.4M	NEW
Vanguard	2.61M	$18.95M	+0.6%
AltraVue Capital	1.9M	$12.25M	-0.7%
Jet Capital Investors L P	1.71M	$12.43M	+3.6%
Price Michael F	1.21M	$8.77M	0.0%
STT State Street	1.04M	$7.58M	-0.6%
Geode Capital Management	791.59K	$5.75M	+0.5%
Arrowstreet Capital, Limited Partnership	621.12K	$4.52M	+7.4%
NTRS Northern Trust	595K	$4.33M	-3.1%

Largest transactions	Shares	Bought/sold	Change
Esopus Creek Value Series Fund LP - Series A	3.49M	+3.49M	NEW
Nantahala Capital Management	321.03K	-654.41K	-67.1%
Millennium Management	0	-180.05K	EXIT
Oaktree Capital Management	0	-159.78K	EXIT
Martingale Asset Management L P	28.91K	-136.57K	-82.5%
Citadel Advisors	19.38K	-114.02K	-85.5%
BK Bank Of New York Mellon	302.5K	+76.26K	+33.7%
BLK Blackrock	4.54M	-74.39K	-1.6%
Two Sigma Investments	109.11K	-66.32K	-37.8%
MS Morgan Stanley	75.79K	+64.23K	+555.9%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Chimerix • Emergent Biosolutions • Tonix Pharmaceuticals Holding

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: accredited, Aid, Authorisation, BR, Brazil, bribery, building, centralized, coordinated, coordinating, coordination, correction, daily, discharged, division, driven, economy, Eli, EMA, EU, exemption, expressed, expressing, extinguishment, home, Iceland, incentivizing, inclusion, indeterminate, Inline, input, insufficient, Interactive, intermediate, issuable, Kane, Liechtenstein, Lilly, MAA, makewhole, margin, Norway, oversee, overseeing, pace, Page, par, PHAC, preceded, preceding, premium, recoverability, referenced, retired, SNS, societal, solicitation, surge, surrendered, teamwork, therewith, underwriting, unexpired, upgrading, voluntarily, warm

Removed: accelerate, accreted, administered, advisory, allocation, assessed, assume, attract, attribute, bankruptcy, broaden, capped, climate, Codification, conflicting, consolidation, constraining, continuance, dedicate, dedication, demonstrated, difficulty, dispose, disproportionate, downgrade, eliminate, emerging, enforced, Exit, expiring, extreme, failed, feedback, flexibility, fluctuate, foreclose, foregoing, formulating, hospital, hypothetical, impede, improve, inaccuracy, inaccurate, initiate, initiating, insolvency, intangible, Integrated, Justice, licensed, lien, magnitude, media, merger, minimal, optioned, orally, owing, permanently, physician, professional, profitably, prohibited, prospectively, publish, qualitative, quantitative, rejection, relieve, remain, Replacing, researching, revolving, royalty, selected, settled, shortening, skilled, SSAR, step, strain, sublet, sustain, tangible, technique, thereto, title, Unaudited, unchanged, unpaid, unreimbursed, unrelated, volume, wrote

From filing 10-K 2020 FY